Nektar Therapeutics - Product Pipeline Review - 2014

Published: May, 2014 | Pages: 67 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Nektar Therapeutics - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Nektar Therapeutics - Product Pipeline Review - 2014', provides an overview of the Nektar Therapeutics's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Nektar Therapeutics's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Nektar Therapeutics including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Nektar Therapeutics's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Nektar Therapeutics's pipeline products

Reasons to buy

- Evaluate Nektar Therapeutics's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Nektar Therapeutics in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Nektar Therapeutics's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Nektar Therapeutics and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Nektar Therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Nektar Therapeutics and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Nektar Therapeutics Snapshot 6
Nektar Therapeutics Overview 6
Key Information 6
Key Facts 6
Nektar Therapeutics - Research and Development Overview 7
Key Therapeutic Areas 7
Nektar Therapeutics - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Pipeline Products - Out-Licensed Products 14
Out-Licensed Products/Combination Treatment Modalities 15
Nektar Therapeutics - Pipeline Products Glance 16
Nektar Therapeutics - Late Stage Pipeline Products 16
Phase III Products/Combination Treatment Modalities 16
Nektar Therapeutics - Clinical Stage Pipeline Products 17
Phase II Products/Combination Treatment Modalities 17
Phase I Products/Combination Treatment Modalities 18
Nektar Therapeutics - Early Stage Pipeline Products 19
Preclinical Products/Combination Treatment Modalities 19
Discovery Products/Combination Treatment Modalities 20
Nektar Therapeutics - Drug Profiles 21
etirinotecan pegol 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
NKTR-181 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
NKTR-171 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Longer Acting Therapeutic Clotting Proteins 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
NKTR-125 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
NKTR-140 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
NKTR-174 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
NKTR-192 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
NKTR-194 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
NKTR-195 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
NKTR-196 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
NKTR-214 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NKTR-223 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
NKTR-228 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Antiviral Cytokine 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Cytokine For Oncology 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Folate Inhibitor For Oncology 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Kinase Inhibitor 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Protein to Agonize Cytokine Receptor for Inflammation 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Antagonize NMDA Receptor for Pain and Depression 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Nektar Therapeutics - Pipeline Analysis 44
Nektar Therapeutics - Pipeline Products by Target 44
Nektar Therapeutics - Pipeline Products by Route of Administration 46
Nektar Therapeutics - Pipeline Products by Molecule Type 47
Nektar Therapeutics - Pipeline Products by Mechanism of Action 48
Nektar Therapeutics - Recent Pipeline Updates 50
Nektar Therapeutics - Dormant Projects 59
Nektar Therapeutics - Discontinued Pipeline Products 60
Discontinued Pipeline Product Profiles 60
NKTR-105 60
NKTR-192 60
Nektar Therapeutics - Company Statement 61
Nektar Therapeutics - Locations And Subsidiaries 64
Head Office 64
Other Locations & Subsidiaries 64
Appendix 66
Methodology 66
Coverage 66
Secondary Research 66
Primary Research 66
Expert Panel Validation 66
Contact Us 67
Disclaimer 67

List of Tables
Nektar Therapeutics, Key Information 6
Nektar Therapeutics, Key Facts 6
Nektar Therapeutics - Pipeline by Indication, 2014 8
Nektar Therapeutics - Pipeline by Stage of Development, 2014 10
Nektar Therapeutics - Monotherapy Products in Pipeline, 2014 11
Nektar Therapeutics - Partnered Products in Pipeline, 2014 12
Nektar Therapeutics - Partnered Products/ Combination Treatment Modalities, 2014 13
Nektar Therapeutics - Out-Licensed Products in Pipeline, 2014 14
Nektar Therapeutics - Out-Licensed Products/ Combination Treatment Modalities, 2014 15
Nektar Therapeutics - Phase III, 2014 16
Nektar Therapeutics - Phase II, 2014 17
Nektar Therapeutics - Phase I, 2014 18
Nektar Therapeutics - Preclinical, 2014 19
Nektar Therapeutics - Discovery, 2014 20
Nektar Therapeutics - Pipeline by Target, 2014 45
Nektar Therapeutics - Pipeline by Route of Administration, 2014 46
Nektar Therapeutics - Pipeline by Molecule Type, 2014 47
Nektar Therapeutics - Pipeline Products by Mechanism of Action, 2014 49
Nektar Therapeutics - Recent Pipeline Updates, 2014 50
Nektar Therapeutics - Dormant Developmental Projects,2014 59
Nektar Therapeutics - Discontinued Pipeline Products, 2014 60
Nektar Therapeutics, Other Locations 64
Nektar Therapeutics, Subsidiaries 65